터제파타이드(Tirzepatide)는 2형 당뇨와 비만 치료로 미국 FDA 승인을 받은 최신 약물로, 기존 GLP-1 수용체 작용제보다 강력한 혈당 조절과 체중 감량 효과로 주목받고 있다. 그런데 이 약이 혈관 건강에도 직접적인 이점을 줄 수 있다는 동물 실험 및 세포 실험 결과가 나왔다.
심양의과대학 혈관생물학 연구소 등 공동 연구팀이 *Archives of Pharmacal Research*에 발표한 이 연구는 동맥경화 발생에 취약한 아포E 결핍(apoE-/-) 마우스에게 12주간 고지방·고콜레스테롤 식이를 제공하면서 터제파타이드 투여군과 비투여군의 차이를 분석했다. 또한 배양 대식세포에 산화된 저밀도 지단백(oxLDL)을 처리해 거품세포 형성과 염증에 대한 약물 효과를 평가했다.
동물 실험 결과, 터제파타이드는 체중, 혈중 지질, 동맥경화 병변 부담을 유의하게 감소시켰다. 특히 M1(염증 촉진)/M2(항염증) 대식세포의 균형도 개선됐다. ANCOVA 분석을 통해 항동맥경화 효과 일부가 대사 개선과 독립적인 경로를 통해 나타날 수 있음을 시사했다 — 즉, 체중이나 혈당이 줄어서만이 아니라 혈관 자체에 직접 작용하는 기전이 있을 수 있다는 것이다.
세포 실험에서는 더 명확한 결과가 나왔다. 터제파타이드는 oxLDL에 의한 콜레스테롤 축적과 거품세포 형성을 억제하고, 염증 촉진 M1 표지자를 줄이면서 항염증 M2 표지자를 높였다. 이 효과는 GLP-1 수용체와 GIP 수용체를 동시에 차단했을 때 사라졌다. 핵심 분자 기전으로 KLF4/PPARγ 경로 활성화가 확인됐으며, 이는 대식세포의 염증 조절과 플라크 안정화에 중요한 역할을 한다.
연구팀은 터제파타이드의 심혈관 보호 효과가 지질 저하 의존적 기전과 독립적 기전을 모두 포함한다고 결론지었다. 이는 당뇨·비만으로 심혈관 고위험군에 있는 환자들에게 터제파타이드가 혈당·체중 조절 이상의 추가 심혈관 혜택을 제공할 가능성을 시사한다.
다만 이번 연구는 동물 모델과 세포 실험에 기반하므로 인체에서의 효과를 직접 증명하지는 않는다. 현재 터제파타이드의 심혈관 결과를 평가하는 대규모 무작위 임상 시험(SURPASS-CVOT 등)이 진행 중이며, 최종 결과를 확인해야 임상적 적용을 판단할 수 있다.
터제파타이드나 유사 약물을 복용 중인 당뇨·비만 환자는 약물 효과를 극대화하기 위해 지중해식 식이, 규칙적인 운동, 금연, 혈압 관리 등 기본 심혈관 위험 인자 관리를 병행해야 한다.
📖 *Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages (동물 실험 및 세포 실험)* |
논문 원문
※ 이 기사는 의학 논문을 바탕으로 작성되었습니다. 개인 건강 상태에 따라 다를 수 있으니 전문의와 상담하세요.
Tirzepatide has become one of the most talked-about drugs in recent medical history, delivering remarkable reductions in blood sugar and body weight in patients with type 2 diabetes and obesity. But could it also be protecting their arteries — independent of those metabolic improvements? New preclinical research suggests the answer may be yes.
A study published in *Archives of Pharmacal Research* investigated tirzepatide's anti-atherosclerotic effects in a well-established mouse model of cardiovascular disease and in cultured human macrophages, uncovering molecular mechanisms that extend well beyond cholesterol lowering.
The Drug and Why It Matters
Tirzepatide (TZP) is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It stimulates insulin secretion, reduces appetite, and promotes weight loss more powerfully than earlier GLP-1 single-agonists. Its cardiovascular effects are under intense investigation because patients with type 2 diabetes and obesity are among the highest-risk groups for atherosclerotic heart disease.
What the Animal Study Showed
Researchers used apolipoprotein E-deficient (apoE-/-) mice — a standard model for atherosclerosis research — fed a high-fat, high-cholesterol diet for 12 weeks, with or without tirzepatide treatment.
Tirzepatide-treated animals showed significant reductions in body weight, plasma lipid levels, and the size and burden of atherosclerotic lesions compared with untreated controls. The drug also favorably shifted the balance of M1 (pro-inflammatory) to M2 (anti-inflammatory) macrophages within atherosclerotic plaques — a shift associated with plaque stabilization rather than rupture.
The study then took an important additional step: using ANCOVA analysis, researchers found that the anti-atherosclerotic effect was partially independent of the metabolic improvements in weight and lipids. The qualification "partially" is important — the authors note that further studies are needed to confirm this independence, and that other vascular cells and plaque components likely contribute to the observed benefits.
Macrophage Experiments Reveal the Mechanism
To understand how tirzepatide modulates inflammation in artery plaques, the team exposed RAW264.7 and THP-1 macrophages (the latter being human-derived) to oxidized LDL (oxLDL) — the form of cholesterol most directly implicated in foam cell formation and plaque development.
Tirzepatide inhibited oxLDL-induced cholesterol accumulation and foam cell formation, reduced expression of pro-inflammatory M1 markers (including CD36, the scavenger receptor that facilitates cholesterol uptake), and boosted anti-inflammatory M2 markers. These effects were abolished when both the GLP-1 and GIP receptors were simultaneously blocked, confirming that dual receptor engagement is required.
Mechanistically, tirzepatide's anti-inflammatory effects operated through activation of the KLF4/PPARγ pathway — a transcriptional axis that promotes an anti-inflammatory macrophage phenotype and suppresses the inflammatory cascades that destabilize plaques.
Why This Matters Clinically
If tirzepatide can reduce plaque burden and stabilize existing plaques through direct vascular mechanisms — not just by improving metabolic parameters — it would represent a meaningful additional cardiovascular benefit for the diabetic and obese patients who receive it. These are precisely the patients at highest risk for heart attacks and strokes driven by unstable atherosclerotic plaques.
Important Caveats
This research was conducted entirely in mice and cell culture models. Animal studies of atherosclerosis, while valuable for mechanistic insights, do not always translate directly to human clinical outcomes. The definitive answer on tirzepatide's cardiovascular effects will come from ongoing large-scale randomized controlled trials, including the SURPASS-CVOT trial, which is specifically designed to measure cardiovascular event rates.
In the meantime, patients taking tirzepatide for diabetes or obesity should maintain all established cardiovascular risk management strategies: blood pressure control, a heart-healthy diet, regular exercise, and smoking cessation.
📖 *Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages (Animal and cell study)* |
Source
※ This article is based on a published medical study. Individual health circumstances vary — consult your physician before making any changes to your care.
